Poxel SA is a clinical-stage biopharmaceutical company, which engages in the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as non-alcoholic steatohepatitis (NASH). The company is headquartered in Lyon, Auvergne-Rhone-Alpes. The company went IPO on 2015-02-06. The firm develops drugs with a focus on Type 2 diabetes. The firm aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication. A direct activator of AMPK for the treatment of Type 2 diabetes has started its preclinical development, and other projects in the research phase target diabetes and other metabolic diseases with small molecules that have a disease-modifying mechanism of action. Poxel SAS was spun out from Merck Serono. The firm cooperates with the Laboratory for Fundamental and Applied Bioenergetics, Sumitomo Dainippon Pharma, Joseph Fourier University and Department of Cell Physiology and Metabolism at the University of Geneva, Switzerland, among others.
Follow-Up Questions
Poxel SA のCEOは誰ですか？
Mr. Nicolas Trouche は Poxel SA の Chief Executive Officer で、2025 から在籍しています。
PXXLF の株価パフォーマンスは？
PXXLF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Poxel SA の主な事業テーマや業界は？
Poxel SA は Biotechnology 業界、セクターは Health Care に属しています。
